Nonlamellar Phases in Cationic Phospholipids, Relevance to Drug and Gene Delivery
Source abstract
Abstract
Lipid aggregates have been used as drug carriers for several decades. Recently, nonlamellar liquid crystalline lipid systems have attracted attention as possible drug-delivery vehicles because of their unique nanostructure and physicochemical properties. Here we summarize data on the nonlamellar phase-forming propensity of the cationic phosphatidylcholines (cationic PCs). The class of cationic PCs has been specifically designed and explored for the purpose of nonviral gene delivery. These lipids were found to comprise an attractive cationic lipid class because they are biodegradable, have low toxicities, and in a number of cases, display high transfection activity. Lipids of this class form a variety of polymorphic and mesomorphic phases-lamellar and nonlamellar, depending on the structure of their hydrocarbon chains and especially on the third hydrocarbon chain used to alkylate the PC phosphate group and convert the zwitterionic PC headgroup into a cation. Here we characterize the phase behavior and transfection activity of eight cationic PCs that have been identified as forming nonlamellar phases-inverted hexagonal and cubic. We then demonstrate that those cationic PCs that also form nonlamellar lipoplexes are notably less efficient gene nanocarriers in comparison with the cationic PCs forming lamellar phase lipoplexes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · HIV Research and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Pharmacy, The Ohio State University, 517 Parks Hall, 500 W. 12th Avenue, Columbus, Ohio 43210, United States
Department of Molecular Biosciences, Northwestern University, Evanston, Illinois, United States
Department of Medical Physics and Biophysics, Medical University−Sofia, Sofia, Bulgaria
References (55)
Show source-provided references
1. 10.1016/S0022-2836(64)80115-710.1016/S0022-2836(64)80115-7 ↗
2. 10.2174/1872211311307999001110.2174/18722113113079990011 ↗
3. 10.1038/337387a010.1038/337387a0 ↗
4. 10.1016/0005-2736(90)90017-I10.1016/0005-2736(90)90017-I ↗
5. 10.1016/0006-291X(91)91366-K10.1016/0006-291X(91)91366-K ↗
6. 10.1002/(SICI)1521-2254(199907/08)1:4<290::AID-JGM47>3.3.CO;2-310.1002/(SICI)1521-2254(199907/08)1:4<290::AID-JGM47>3.3.CO;2-3 ↗
7. Giacca M. · Int. J. Nanomed. · 2007 · 2 · 527
8. 10.1016/j.ymthe.2005.04.00610.1016/j.ymthe.2005.04.006 ↗
9. 10.1021/js990006q10.1021/js990006q ↗
10. 10.1016/S0006-3495(99)77095-510.1016/S0006-3495(99)77095-5 ↗
11. 10.1006/mthe.1999.000910.1006/mthe.1999.0009 ↗
12. 10.1002/jps.108610.1002/jps.1086 ↗
13. 10.1023/A:101190253216310.1023/A:1011902532163 ↗
14. 10.1038/sj.gt.330047310.1038/sj.gt.3300473 ↗
15. 10.1002/jgm.55010.1002/jgm.550 ↗
16. 10.1016/j.bbamem.2006.12.01710.1016/j.bbamem.2006.12.017 ↗
17. 10.1016/j.jconrel.2007.12.00510.1016/j.jconrel.2007.12.005 ↗
18. Tenchov B. · Anticancer Res. · 2012 · 32 · 2563
19. 10.1146/annurev.pc.25.100174.00045510.1146/annurev.pc.25.100174.000455 ↗
20. Seddon J. M. · 1995 · 97
21. 10.1126/science.281.5373.7810.1126/science.281.5373.78 ↗
22. 10.1007/s00232-002-1015-710.1007/s00232-002-1015-7 ↗
23. 10.1074/jbc.M10619920010.1074/jbc.M106199200 ↗
24. 10.1074/jbc.M10558820010.1074/jbc.M105588200 ↗
25. Engstrom, S.; Larson, K.; Lindman, B.; Engstroem, S.; Larsson, K. V.:Controlled-release compsn. for biologically active material - comprising L 2-phase contg. a mono:glyceride, a tri-glyceride and a polar liq. DRILLETTEN AB (DRIL-Non-standard) ENGSTROM S (ENGS-Individual), 1988.
26. Engstrom, S.; Larsson, K.; Lindman, B.; Engstroem, S.:Prepn. of controlled release compsn. for biologically active material - from amphipathic agents to give cubic liq. crystal phase. FLUIDCARBON INTERNATIONAL AB (FLUI-Non-standard) ENGSTROM S (ENGS-Individual) FLUID CARBON INT AB (FLUI-Non-standard) FLUIDCRYSTAL I MALMO AB (FLUI-Non-standard) FLUIDCRYSTAL I MALMOE AB (FLUI-Non-standard) GS DEV AB (GSGS-Non-standard), 1984.
27. Landh, T.; Larssons, K.; Larsson, K.[Anon]: Low birefringence liquid crystal|form stable dispersions useful for e.g. sustained drug delivery, antigen presentation, nucleic acid transport etc. GS BIOCHEM AB GS DEV AB.
28. 10.1055/s-1996-545710.1055/s-1996-5457 ↗
29. 10.1021/bc990114410.1021/bc9901144 ↗
30. 10.1021/mp800011e10.1021/mp800011e ↗
31. 10.1529/biophysj.106.09270010.1529/biophysj.106.092700 ↗
32. Rakhmanova V. A. · Cell. Mol. Biol. Lett. · 2000 · 5 · 51
33. 10.1016/S0005-2736(03)00135-410.1016/S0005-2736(03)00135-4 ↗
34. 10.1039/b902027f10.1039/b902027f ↗
35. 10.1017/S003358350000164510.1017/S0033583500001645 ↗
36. Kasper J. S. · 1985
37. 10.1016/S0304-4157(98)00006-910.1016/S0304-4157(98)00006-9 ↗
38. 10.1007/s00249-012-0819-310.1007/s00249-012-0819-3 ↗
39. Koynova R. · Lipid Insights · 2008 · 41
40. 10.1529/biophysj.106.08376610.1529/biophysj.106.083766 ↗
41. 10.1016/S0005-2736(01)00283-810.1016/S0005-2736(01)00283-8 ↗
42. 10.1021/ja962713g10.1021/ja962713g ↗
43. 10.1016/S0014-5793(97)00505-X10.1016/S0014-5793(97)00505-X ↗
44. 10.1126/science.275.5301.81010.1126/science.275.5301.810 ↗
45. 10.1021/mp800257310.1021/mp8002573 ↗
46. 10.1016/j.bbamem.2008.07.02210.1016/j.bbamem.2008.07.022 ↗
47. Griffin W. C. · J. Soc. Cosmet. Chem. · 1949 · 1 · 311
48. 10.1209/epl/i2004-10091-y10.1209/epl/i2004-10091-y ↗
49. 10.1016/j.colsurfb.2004.04.00610.1016/j.colsurfb.2004.04.006 ↗
50. 10.3109/0898210980903993410.3109/08982109809039934 ↗
51. 10.1038/303612a010.1038/303612a0 ↗
52. 10.1073/pnas.060308510310.1073/pnas.0603085103 ↗
53. 10.1016/j.bbamem.2006.10.01610.1016/j.bbamem.2006.10.016 ↗
54. 10.1021/bc050226x10.1021/bc050226x ↗
55. 10.3109/08982104.2011.56547610.3109/08982104.2011.565476 ↗